Avinoam Shiran
Research Subjects
Avinoam Shiran has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
- Basil S. Lewis
Department of Cardiology, Lady Davis Carmel Medical Center, Haifa, Israel
7 shared publications - David A. Halon
Cardiovascular Clinical Research Institute, Lady Davis Carmel Medical Center, Haifa, Israel
5 shared publications - Amnon Y. Zlotnick
Department of Cardiothoracic Surgery, Lady Davis Carmel Medical Center and the Ruth and Bruce Rappaport Faculty of Medicine, Technion, Israel
3 shared publications Basheer Karkabi
3 shared publicationsDan Aravot
From the Departments of Cardiothoracic Surgery (A.Y.Z., D.A.) and Cardiovascular Medicine (A.S., B.S.L.), Lady Davis Carmel Medical Center, and the Ruth and Bruce Rappaport Faculty of Medicine, Technion–Israel Institute of Technology, Haifa, Israel
3 shared publications- Alexandre Abizaid
Universidade de São Paulo
2 shared publications
Latest Publications
- 1 May 2015
- Vol. 17 (5) , 288-92
Association of Vitamin B12 Deficiency with Homozygosity of the TT MTHFR C677T Genotype, Hyperhomocysteinemia, and Endothelial Cell Dysfunction.
Hyperhomocysteinemia is associated with increased cardiovascular risk, but treatment with folic acid has no effect on outcome in unselected patient populations. To confirm previous observations on the association of homozygosity for the TT MTHFR genotype with B12 deficiency and endothelial dysfunction, and to investigate whether patients with B12 deficiency should be tested for 677MTHFR genotype. We enrolled 100 individuals with B12 deficiency, tested them for the MTHFR C677T polymorphism and measured their homocysteine levels. Forearm endothelial function was checked in 23 B12-deficient individuals (13 with TT MTHFR genotype and 10 with CT or CC genotypes). Flow-mediated dilatation (FMD) was tested after short-term treatment with B12 and folic acid in 12 TT MTHFR homozygotes. Frequency of the TT MTHFR genotype was 28/100 (28%), compared with 47/313 (15%) in a previously published cohort of individuals with normal B12 levels (P = 0.005). Mean homocysteine level was 21.2 ± 16 μM among TT homozygotes as compared to 12.3 ± 5.6 μM in individuals with the CC or CT genotype (P = 0.008). FMD was abnormal ( 6%) in 9/13 TT individuals with B12 deficiency (69%), and was still abnormal in 7/12 of those tested 6 weeks after B12 and folic treatment (58%). Among individuals with B12 deficiency, the frequency of the TT MTHFR genotype was particularly high. The TT polymorphism was associated with endothelial dysfunction even after 6 weeks of treatment with B12 and folic acid. Based on our findings we suggest that B12 deficiency be tested for MTHFR polymorphism in order to identify potential vascular abnormalities and increased cardiovascular risk.
- 1 May 2015
- Vol. 17 (5) , 288-92
Association of Vitamin B12 Deficiency with Homozygosity of the TT MTHFR C677T Genotype, Hyperhomocysteinemia, and Endothelial Cell Dysfunction.
Hyperhomocysteinemia is associated with increased cardiovascular risk, but treatment with folic acid has no effect on outcome in unselected patient populations. To confirm previous observations on the association of homozygosity for the TT MTHFR genotype with B12 deficiency and endothelial dysfunction, and to investigate whether patients with B12 deficiency should be tested for 677MTHFR genotype. We enrolled 100 individuals with B12 deficiency, tested them for the MTHFR C677T polymorphism and measured their homocysteine levels. Forearm endothelial function was checked in 23 B12-deficient individuals (13 with TT MTHFR genotype and 10 with CT or CC genotypes). Flow-mediated dilatation (FMD) was tested after short-term treatment with B12 and folic acid in 12 TT MTHFR homozygotes. Frequency of the TT MTHFR genotype was 28/100 (28%), compared with 47/313 (15%) in a previously published cohort of individuals with normal B12 levels (P = 0.005). Mean homocysteine level was 21.2 ± 16 μM among TT homozygotes as compared to 12.3 ± 5.6 μM in individuals with the CC or CT genotype (P = 0.008). FMD was abnormal ( 6%) in 9/13 TT individuals with B12 deficiency (69%), and was still abnormal in 7/12 of those tested 6 weeks after B12 and folic treatment (58%). Among individuals with B12 deficiency, the frequency of the TT MTHFR genotype was particularly high. The TT polymorphism was associated with endothelial dysfunction even after 6 weeks of treatment with B12 and folic acid. Based on our findings we suggest that B12 deficiency be tested for MTHFR polymorphism in order to identify potential vascular abnormalities and increased cardiovascular risk.
- 30 October 2010
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Imaging
- Vol. 12 (3) , E12
Echocardiographic Brockenbrough–Braunwald–Morrow sign
The Brockenbrough-Braunwald-Morrow sign is the paradoxical decrease in pulse pressure during the post-extrasystole beat seen in patients with hypertrophic obstructive cardiomyopathy. We present a case of intermittent left ventricular outflow tract obstruction and secondary mitral regurgitation resulting from post-extrasystolic potentiation following a premature atrial beat, demonstrating using echocardiography the mechanism behind this sign.
- 30 October 2010
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Imaging
- Vol. 12 (3) , E12
Echocardiographic Brockenbrough–Braunwald–Morrow sign
The Brockenbrough-Braunwald-Morrow sign is the paradoxical decrease in pulse pressure during the post-extrasystole beat seen in patients with hypertrophic obstructive cardiomyopathy. We present a case of intermittent left ventricular outflow tract obstruction and secondary mitral regurgitation resulting from post-extrasystolic potentiation following a premature atrial beat, demonstrating using echocardiography the mechanism behind this sign.
- 4 August 2008
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Imaging
- Vol. 10 (2) , 319-324
Accuracy and reproducibility of left ventricular outflow tract diameter measurement using transthoracic when compared with transesophageal echocardiography in systole and diastole
Accurate measurement of left ventricular outflow tract diameter (LVOTd) is essential for reliable estimation of aortic valve area (AVA) using the continuity equation. Transesophageal echocardiography (TEE) can accurately delineate the LVOT. The aim of this study was to assess the accuracy and reproducibility of LVOTd measurement using transthoracic echocardiography (TTE) with harmonic imaging when compared with TEE, in both systole and diastole. We prospectively studied 50 patients [20 with aortic stenosis (AS) and 30 without AS]. LVOTd was measured offline in a blinded fashion in both systole and diastole by two experienced observers using TTE in the parasternal long axis view and TEE in the mid-oesophageal aortic view ( approximately 130 degrees ). There was strong correlation between TTE and TEE (r=0.91). LVOTd was slightly smaller by TTE when compared with TEE (2.11+/-0.21 vs. 2.16+/-0.22 cm, mean difference -0.05+/-0.09 cm, P=0.0003). Compared with TEE, 95% (2SD) of LVOTd measurements by TTE were within +0.14 and -0.24 cm. Inter- and intra-observer variability for LVOTd was 4.8+/-4.1 and 2.8+/-1.9% for TTE and 4.2+/-3.1 and 2.5+/-1.6% for TEE (P=0.4 and 0.6). In patients with AS, estimated AVA was 0.93+/-0.22 cm(2) using TTE and 0.96+/-0.24 cm(2) using TEE, P=0.08. Diastolic LVOTd by TEE was slightly smaller compared with systolic LVOTd by TEE (-0.03+/-0.07 cm, P=0.0005), and there was strong correlation between the two (r=0.95). We present the data regarding accuracy and reproducibility of LVOTd measurements by TTE when compared with TEE. LVOTd measurements at end-diastole may be helpful when systolic images are suboptimal.
- 4 August 2008
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Imaging
- Vol. 10 (2) , 319-324
Accuracy and reproducibility of left ventricular outflow tract diameter measurement using transthoracic when compared with transesophageal echocardiography in systole and diastole
Accurate measurement of left ventricular outflow tract diameter (LVOTd) is essential for reliable estimation of aortic valve area (AVA) using the continuity equation. Transesophageal echocardiography (TEE) can accurately delineate the LVOT. The aim of this study was to assess the accuracy and reproducibility of LVOTd measurement using transthoracic echocardiography (TTE) with harmonic imaging when compared with TEE, in both systole and diastole. We prospectively studied 50 patients [20 with aortic stenosis (AS) and 30 without AS]. LVOTd was measured offline in a blinded fashion in both systole and diastole by two experienced observers using TTE in the parasternal long axis view and TEE in the mid-oesophageal aortic view ( approximately 130 degrees ). There was strong correlation between TTE and TEE (r=0.91). LVOTd was slightly smaller by TTE when compared with TEE (2.11+/-0.21 vs. 2.16+/-0.22 cm, mean difference -0.05+/-0.09 cm, P=0.0003). Compared with TEE, 95% (2SD) of LVOTd measurements by TTE were within +0.14 and -0.24 cm. Inter- and intra-observer variability for LVOTd was 4.8+/-4.1 and 2.8+/-1.9% for TTE and 4.2+/-3.1 and 2.5+/-1.6% for TEE (P=0.4 and 0.6). In patients with AS, estimated AVA was 0.93+/-0.22 cm(2) using TTE and 0.96+/-0.24 cm(2) using TEE, P=0.08. Diastolic LVOTd by TEE was slightly smaller compared with systolic LVOTd by TEE (-0.03+/-0.07 cm, P=0.0005), and there was strong correlation between the two (r=0.95). We present the data regarding accuracy and reproducibility of LVOTd measurements by TTE when compared with TEE. LVOTd measurements at end-diastole may be helpful when systolic images are suboptimal.
- 1 August 2008
- Vol. 20 (8) , 411-6
Two-year intravascular ultrasound observations in diabetic patients treated with single and double dose sirolimus-eluting stents: results of the double dose diabetes (3D) study.
Diabetes has been reported as an independent predictor of restenosis after drug-eluting stent implantation. The purpose of this study was to assess the long-term impact of increased drug dose in sirolimus-eluting stents (SES) on neointimal hyperplasia (NIH) in diabetic patients using volumetric intravascular ultrasound analysis. The 3D trial is a multicenter, prospective, randomized, feasibility study of double-dose (280 microg/cm2) or conventional single-dose (140 microg/cm2) SES for the treatment of de novo coronary lesions in diabetic patients. To evaluate long-term efficacy, complete serial volumetric analyses (baseline, 6-month and 2-year follow up) were performed in 39 diabetic patients (17 single-dose, 22 double-dose). Each volume was divided by stent length to acquire volume index, expressed as mm3/mm. Percent neointimal volume was calculated as (neointimal volume/stent volume) x 100 at follow up. Volumetric analysis showed similar results over time between the 2 stent groups (p = NS for all). At 2-year follow up, minimal increases in NIH area and percent NIH were observed in both groups, which translated into a decrease in lumen volume index compared to baseline (p < 0.05 for all). No late-acquired incomplete stent apposition was observed in either group. The current single dose of sirolimus in SES is effective in inhibiting NIH in diabetic patients up to 2 years. In this patient subset, double-dose SES did not confer additional NIH suppression at 2-year follow up compared to conventional single-dose SES.
- 1 August 2008
- Vol. 20 (8) , 411-6
Two-year intravascular ultrasound observations in diabetic patients treated with single and double dose sirolimus-eluting stents: results of the double dose diabetes (3D) study.
Diabetes has been reported as an independent predictor of restenosis after drug-eluting stent implantation. The purpose of this study was to assess the long-term impact of increased drug dose in sirolimus-eluting stents (SES) on neointimal hyperplasia (NIH) in diabetic patients using volumetric intravascular ultrasound analysis. The 3D trial is a multicenter, prospective, randomized, feasibility study of double-dose (280 microg/cm2) or conventional single-dose (140 microg/cm2) SES for the treatment of de novo coronary lesions in diabetic patients. To evaluate long-term efficacy, complete serial volumetric analyses (baseline, 6-month and 2-year follow up) were performed in 39 diabetic patients (17 single-dose, 22 double-dose). Each volume was divided by stent length to acquire volume index, expressed as mm3/mm. Percent neointimal volume was calculated as (neointimal volume/stent volume) x 100 at follow up. Volumetric analysis showed similar results over time between the 2 stent groups (p = NS for all). At 2-year follow up, minimal increases in NIH area and percent NIH were observed in both groups, which translated into a decrease in lumen volume index compared to baseline (p < 0.05 for all). No late-acquired incomplete stent apposition was observed in either group. The current single dose of sirolimus in SES is effective in inhibiting NIH in diabetic patients up to 2 years. In this patient subset, double-dose SES did not confer additional NIH suppression at 2-year follow up compared to conventional single-dose SES.
- Open Access
- 22 July 2008
- Published by Wolters Kluwer Health in Circulation
- Vol. 118 (4) , e73-e75
Acute Reversible Bioprosthetic Mitral Valve Stenosis Caused by Heparin-Induced Thrombocytopenia
- 22 July 2008
- Published by Wolters Kluwer Health in Circulation
- Vol. 118 (4) , e73-e75
Open AccessAcute Reversible Bioprosthetic Mitral Valve Stenosis Caused by Heparin-Induced Thrombocytopenia
- Open Access
- 1 January 2008
- Published by Wolters Kluwer Health in Circulation
- Vol. 117 (1) , e1-e2
A Perfectly Functioning Magovern-Cromie Sutureless Prosthetic Aortic Valve 42 Years After Implantation
- 1 January 2008
- Published by Wolters Kluwer Health in Circulation
- Vol. 117 (1) , e1-e2
Open AccessA Perfectly Functioning Magovern-Cromie Sutureless Prosthetic Aortic Valve 42 Years After Implantation
- 1 July 2007
- Vol. 16 (4) , 336-43
Non-myxomatous flail mitral valve: clinical and echocardiographic characteristics and long-term clinical outcome.
Chordal rupture leading to flail mitral valve and mitral regurgitation (MR) is considered to be caused primarily by myxomatous mitral valve disease. The study aim was to determine the prevalence and clinical and echocardiographic characteristics of non-myxomatous versus myxomatous flail mitral valve. A total of 96 patients with flail mitral valve was identified from an echocardiography database and classified as either myxomatous (n = 36; 37%) or non-myxomatous (n = 60; 63%), based on echocardiographic mitral valve anatomy (systolic leaflet buckling). In 10 other patients the etiology was indeterminate. The clinical and echocardiographic characteristics and outcome at five years were compared between groups. Patients with non-myxomatous mitral valve were older than those with myxomatous mitral valve (mean age 76 +/- 9 versus 61 +/- 12 years; p <0.0001), and were more likely to have aortic sclerosis, mitral annulus and papillary muscle calcification (odds ratio 3.6, 95% CI 1.2-10.8, p = 0.02) and to have short duration of symptoms (< or =1 month, p <0.02). There was no inter-group difference in MR severity, but non-myxomatous patients had higher systolic pulmonary artery pressure (52 +/- 16 versus 42 +/- 13 mmHg, p = 0.008). During the five-year follow up period, non-myxomatous patients had a poorer crude survival and survival free from rehospitalization for heart failure (p = 0.02), and were less likely to have mitral valve surgery (p = 0.015). However, these differences were abolished when data were adjusted for age. Among patients with flail mitral valve referred for echocardiography, more than half were non-myxomatous in origin, most likely due to wear and tear. Non-myxomatous flail mitral valve was associated with older age, degenerative calcific valvular changes, and more recent onset of symptoms. Age-adjusted survival free of heart failure was similar in both non-myxomatous and myxomatous patients.
- 1 July 2007
- Vol. 16 (4) , 336-43
Non-myxomatous flail mitral valve: clinical and echocardiographic characteristics and long-term clinical outcome.
Chordal rupture leading to flail mitral valve and mitral regurgitation (MR) is considered to be caused primarily by myxomatous mitral valve disease. The study aim was to determine the prevalence and clinical and echocardiographic characteristics of non-myxomatous versus myxomatous flail mitral valve. A total of 96 patients with flail mitral valve was identified from an echocardiography database and classified as either myxomatous (n = 36; 37%) or non-myxomatous (n = 60; 63%), based on echocardiographic mitral valve anatomy (systolic leaflet buckling). In 10 other patients the etiology was indeterminate. The clinical and echocardiographic characteristics and outcome at five years were compared between groups. Patients with non-myxomatous mitral valve were older than those with myxomatous mitral valve (mean age 76 +/- 9 versus 61 +/- 12 years; p <0.0001), and were more likely to have aortic sclerosis, mitral annulus and papillary muscle calcification (odds ratio 3.6, 95% CI 1.2-10.8, p = 0.02) and to have short duration of symptoms (< or =1 month, p <0.02). There was no inter-group difference in MR severity, but non-myxomatous patients had higher systolic pulmonary artery pressure (52 +/- 16 versus 42 +/- 13 mmHg, p = 0.008). During the five-year follow up period, non-myxomatous patients had a poorer crude survival and survival free from rehospitalization for heart failure (p = 0.02), and were less likely to have mitral valve surgery (p = 0.015). However, these differences were abolished when data were adjusted for age. Among patients with flail mitral valve referred for echocardiography, more than half were non-myxomatous in origin, most likely due to wear and tear. Non-myxomatous flail mitral valve was associated with older age, degenerative calcific valvular changes, and more recent onset of symptoms. Age-adjusted survival free of heart failure was similar in both non-myxomatous and myxomatous patients.
- 1 June 2007
- Published by Elsevier in Journal of the American Society of Echocardiography
- Vol. 20 (6) , 690-697
Intraoperative Transesophageal Echocardiography Using a Quantitative Dynamic Loading Test for the Evaluation of Ischemic Mitral Regurgitation
- 1 June 2007
- Published by Elsevier in Journal of the American Society of Echocardiography
- Vol. 20 (6) , 690-697
Intraoperative Transesophageal Echocardiography Using a Quantitative Dynamic Loading Test for the Evaluation of Ischemic Mitral Regurgitation